Core Viewpoint - Wave Life Sciences announced a positive update from the ongoing RestorAATion-2 trial of WVE-006 for alpha-1 antitrypsin deficiency [2]. Group 1: Company Updates - The press release regarding the trial update was issued and is available in the Investor Relations section of the company's website [2]. - A slide presentation accompanying the conference call will be accessible on the website following the prepared remarks [2]. Group 2: Conference Call Details - The conference call is being recorded, and participants are reminded of this at the beginning of the call [1]. - Forward-looking statements will be discussed during the call, which are subject to various risks and uncertainties [3].

Core Insights - Wave Life Sciences Ltd. is experiencing a decline in stock price following the release of data from the Phase 1b/2a RestorAATion-2 Trial of WVE-006 for alpha-1 antitrypsin deficiency [1] - The company is facing selling pressure in the market [1] Trial Data Summary - The reported data includes results from RestorAATion-2 cohort 1 (200 mg, n=8) where participants received a single subcutaneous dose of WVE-006 followed by seven subcutaneous doses every other week, and the single dose portion of cohort 2 (400 mg, n=8) [2] - WVE-006 demonstrated RNA editing in all treated participants, leading to durable production of serum AAT at levels associated with a lower risk of liver and lung disease after repeat 200 mg doses [3] - Data from both the 200 mg and 400 mg cohorts support a monthly or less frequent subcutaneous dosing regimen, with ongoing dosing in the 400 mg multidose cohort expected to deliver data in the first quarter of 2026 [3] Safety and Licensing - WVE-006 has shown a favorable safety profile and continues to be well-tolerated [4] - GSK Plc holds the exclusive global license for WVE-006, with development and commercialization responsibilities transferring to GSK after the completion of the RestorAATion-2 study [4] Future Developments - Wave Life Sciences is advancing a wholly owned pipeline of RNA editing candidates, with plans to share new preclinical data at Research Day in fall 2025 and to initiate clinical development of additional RNA editing programs in 2026 [5] - As of the publication date, WVE stock is down 21.41% at $7.56 [5]

Summary of Wave Life Sciences (WVE) Update / Briefing September 03, 2025 Company Overview - **Company**: Wave Life Sciences (WVE) - **Focus**: Development of therapies for Alpha-1 Antitrypsin Deficiency (AATD) and RNA editing technologies Key Industry Insights - **AATD Overview**: AATD is caused by the aggregation of mutant ZAAT protein in the liver and a lack of functional AAT in the lungs, leading to severe lung and liver diseases, particularly in homozygous PIZZ individuals [1][2] - **Current Treatments**: Existing treatments are limited to weekly IV augmentation therapy, which does not adequately address the acute phase response during exacerbations [1][2] Core Points and Arguments - **WVE-006 Development**: WVE-006 aims to correct the Z mutation, increasing circulating levels of wild type MAAT protein and reducing mutant ZAAT protein aggregation in the liver [4][5] - **Clinical Trials**: The Restoration 2 clinical trial is evaluating the safety, tolerability, and pharmacokinetics of WVE-006 in individuals with AATD [6][8] - **Safety Profile**: WVE-006 has shown a favorable safety profile with no serious adverse events reported across all doses tested [9][10] - **Biomarker Results**: In the single and multiple dose cohorts, mean max total AAT levels reached 12.9 and 11.9 micromolar, respectively, with MAAT protein levels increasing significantly [10][11] - **Dynamic Response**: WVE-006 demonstrated the ability to restore dynamic physiological AAT production during acute phase responses, a first for AATD therapies [15][17] Additional Important Insights - **RNA Editing Technology**: The proprietary RNA editing technology used in WVE-006 allows for efficient and durable editing, which is crucial for achieving therapeutic effects [19][20] - **Partnership with GSK**: GSK's involvement is expected to enhance the development and commercialization of WVE-006, leveraging their expertise in respiratory medicine [18][19] - **Future Programs**: Wave Life Sciences is advancing additional RNA editing programs, including PNPLA3 for liver disease, with a CTA filing expected in 2026 [19][20] - **Long-term Studies**: There are plans for long-term extension cohorts to gather additional data on repeat dosing and acute phase responses [87][88] Conclusion - **Transformative Potential**: WVE-006 has the potential to transform the treatment landscape for AATD by enabling patients to produce protective AAT protein when needed, addressing both lung and liver manifestations of the disease [17][18] - **Next Steps**: The company anticipates sharing further data from ongoing trials in early 2026, which will provide more insights into the efficacy and safety of WVE-006 [22]

WVE-006 Clinical Trial & Results - WVE-006 achieved durable production of serum AAT at levels associated with lower risk of AATD liver and lung disease following repeat 200 mg doses[5] - In the 200 mg cohort, circulating M-AAT reached 64.4% of total AAT protein[6, 31] - The 200 mg MAD cohort showed a 60.3% decrease in Z-AAT protein[6, 35] - A single 400 mg dose of WVE-006 resulted in total AAT reaching 20.6 µM during an acute phase response[7] - In the 400 mg SAD cohort, circulating M-AAT reached 47.2% of total AAT, with a 49.0% decrease in Z-AAT[41] Safety & Tolerability - WVE-006 was safe and well-tolerated in the RestorAATion-1 healthy volunteer study[26] - WVE-006 continues to be safe and well-tolerated in the RestorAATion-2 clinical trial[29] Ongoing Studies & Future Milestones - A 400 mg monthly multidose cohort is ongoing, with data expected in 1Q 2026[7, 43] - The company anticipates milestone payments in 2025 and beyond[49]

Core Insights - Wave Life Sciences announced positive data from the ongoing Phase 1b/2a RestorAATion-2 study for WVE-006, a treatment for alpha-1 antitrypsin deficiency (AATD), demonstrating durable production of serum AAT protein at levels associated with lower risk of liver and lung diseases [1][3][4] Group 1: Clinical Data and Efficacy - WVE-006 achieved a total AAT level of 11.9 µM and M-AAT level of 7.2 µM in the 200 mg multidose cohort, with M-AAT levels significantly increasing from 4.8 µM during the single dose portion [5][6] - A single 400 mg dose resulted in total AAT of 12.8 µM and M-AAT of 5.3 µM, with M-AAT levels reaching 47.2% of total AAT [8] - The treatment demonstrated the ability to dynamically increase AAT production during acute phase responses, as evidenced by a total AAT level of 20.6 µM observed in one individual during a kidney stone incident [6][10] Group 2: Safety and Tolerability - WVE-006 has shown a favorable safety profile, with all adverse events reported as mild to moderate, and no serious adverse events or discontinuations [9] Group 3: Market Potential and Licensing - Approximately 200,000 individuals in the US and Europe are affected by AATD, with current treatment options limited to weekly IV augmentation therapy, representing over $1.4 billion in worldwide sales in 2023 [2][15] - GSK holds the exclusive global license for WVE-006, with Wave eligible for up to $525 million in milestones and tiered royalties on net sales [11][17] Group 4: Future Developments - Wave plans to share new preclinical data from additional RNA editing programs at a Research Day in fall 2025 and initiate clinical development of new programs in 2026 [12][18]

Core Viewpoint - Wave Life Sciences reported disappointing Q2 2025 earnings, missing revenue and EPS expectations, with significant year-over-year declines in revenue and increased operating expenses [1][5][11] Financial Performance - Q2 2025 revenue was $8.7 million, significantly below the estimated $13.2 million, and down 55.8% from $19.7 million in Q2 2024 [2][5] - EPS loss was $(0.31), worse than the anticipated $(0.28) and a 24.0% increase from $(0.25) in Q2 2024 [2][5] - Net loss for Q2 2025 was $(50.5 million), a 53.5% increase from $(32.9 million) in the prior year [2][5] - Research and Development expenses rose to $43.5 million, a 7.7% increase year-over-year, while General and Administrative expenses increased by 25.9% to $18.0 million [2][5] Company Overview and Strategic Focus - Wave Life Sciences focuses on RNA-based medicines using its proprietary PRISM platform to develop therapies for various genetic disorders [3][4] - The company aims to leverage its technology to create specialized oligonucleotides that enhance drug efficacy and safety [3] Pipeline and Clinical Developments - The company has a diverse pipeline with candidates in clinical testing for obesity, AATD, DMD, and Huntington's disease [4][6] - Progress in AATD with WVE-006 and in obesity with WVE-007 shows promising results, with ongoing trials expected to yield data in Q3 2025 and later [6][7] - WVE-N531 for DMD has shown significant improvement in muscle function, with an NDA filing planned for 2026 [7] Strategic Partnerships and Financial Outlook - No new partnership agreements were established in the quarter, impacting revenue; however, potential future milestone payments from GSK could reach up to $3.3 billion [9][11] - Cash and cash equivalents decreased from $302.1 million at the end of 2024 to $208.5 million by June 30, 2025 [9] - The company expects to fund operations into 2027 with current resources, but this is contingent on future cash spending and partnership developments [11][12] Leadership Changes - Dr. Christopher Wright was appointed as the new Chief Medical Officer to enhance clinical and regulatory operations [10]

Company Performance - Wave Life Sciences reported a quarterly loss of $0.31 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.29, and compared to a loss of $0.25 per share a year ago, indicating a negative earnings surprise of -6.90% [1] - The company posted revenues of $8.7 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 31.16%, and down from $19.69 million in the same quarter last year [2] - Over the last four quarters, Wave Life Sciences has surpassed consensus EPS estimates only once and has also topped consensus revenue estimates just once [2] Stock Performance - Wave Life Sciences shares have declined approximately 32.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.3% [3] - The current Zacks Rank for Wave Life Sciences is 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.29 on revenues of $14.5 million, and for the current fiscal year, it is -$1.12 on revenues of $49.27 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Wave Life Sciences operates, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable industry environment [8]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $8.7 million, a decrease from $19.7 million in the prior year quarter, attributed to the timing of revenue recognized under the collaboration agreement with GSK [28] - Research and development expenses increased to $43.5 million from $40.4 million in the same period in 2024, driven by spending in the inhibin E program and RNA editing programs [28] - General and administrative expenses rose to $18 million from $14.3 million in the prior year quarter, primarily due to share-based compensation and other external expenses [28] - The net loss for Q2 2025 was $50.5 million, compared to a net loss of $32.9 million in the prior year quarter [28] - Cash and cash equivalents at the end of Q2 2025 were $208.5 million, down from $302.1 million as of December 31, 2024, with expectations to fund operations into 2027 [29] Business Line Data and Key Metrics Changes - The AATD clinical program is advancing with promising data from the RESTORATION trials, showing significant increases in circulating AAT levels [7][9] - The Enlight clinical program for obesity has expanded its second cohort from 8 to 32 participants due to favorable safety and tolerability results [10][11] - FORWARD 53 clinical results for DMD demonstrated a statistically significant improvement in time to rise, marking it as a best-in-class therapeutic option [13][14] Market Data and Key Metrics Changes - The company is actively engaging with the DMD community, highlighting the importance of their FORWARD 53 clinical results [12][13] - The obesity market is being targeted with the Enlight program, which is positioned to offer a differentiated approach compared to current standard care [22][24] Company Strategy and Development Direction - The company aims to unlock the potential of RNA medicines through proprietary oligonucleotide chemistry, focusing on both rare and common diseases [4][5] - Plans to initiate clinical development of new programs in 2026, with a focus on expanding their wholly owned discovery pipeline [12][25] - The strategy includes preparing for regulatory filings and engaging with the FDA for accelerated approval pathways [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing clinical programs and the potential for upcoming data readouts to inform the therapeutic pipeline [31] - The company is encouraged by the engagement from the community and clinicians regarding their AATD program, indicating a strong need for effective therapies [6][9] - Future data from the RESTORATION and Enlight trials are expected to serve as key inflection points for the company [12][25] Other Important Information - The company welcomed Dr. Chris Wright as Chief Medical Officer, bringing extensive experience in drug development [5] - The company is focused on addressing both hepatic and extrahepatic targets with their RNA editing and siRNA programs [25][26] Q&A Session Summary Question: Can you elaborate on your reasons for expanding cohort two over advancing to cohort three sooner? - The decision to expand cohort two was based on safety data indicating the ability to dose escalate, and cohort two was modeled to align with weight loss similar to semaglutide [34][36] Question: Should we expect a linear dose response, or does the preservation of lean mass offset the weight loss aspect? - The expectation is that weight loss will be driven by fat without impacting muscle, but human data will clarify the translation of these effects [38] Question: What is your guidance on the different expectations from the two data readouts for the AATD program? - The focus will be on the multidose data, which is expected to show larger liver exposure and higher protein levels compared to single doses [44][46] Question: What is the desirable knockdown level for inhibin E? - The goal is to replicate preclinical data, aiming for a knockdown that aligns with therapeutic weight loss, and the company is open to continuing dose escalation beyond cohort three [51][52] Question: Can you provide specifics on the dosing completion for the two hundred milligram multidose? - All patients in the cohort have received their seven doses, and the study remains on track for data readout in the third quarter [58][59] Question: Is there anything qualitatively about the consistency of effect for the AATD program? - The company is encouraged by the consistency observed in preclinical models and early clinical data, indicating substantial protein production [65][66]

PART I - FINANCIAL INFORMATION [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) This section presents Wave Life Sciences Ltd.'s unaudited consolidated financial statements as of June 30, 2025, detailing balance sheets, operations, equity changes, and cash flows, showing decreased cash and revenue, and increased net loss [Unaudited Consolidated Balance Sheets](index=5&type=section&id=Unaudited%20Consolidated%20Balance%20Sheets) This section provides a snapshot of the company's financial position, detailing assets, liabilities, and equity as of June 30, 2025, compared to December 31, 2024 Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $208,481 | $302,078 | | Total current assets | $223,556 | $320,394 | | Total assets | $252,355 | $352,207 | | Total current liabilities | $87,408 | $110,953 | | Total liabilities | $105,215 | $134,818 | | Total shareholders' equity | $139,266 | $209,515 | [Unaudited Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Unaudited%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) This section details the company's financial performance, including revenue, expenses, and net loss for the three and six months ended June 30, 2025, and 2024 Consolidated Statements of Operations Highlights (in thousands, except per share data) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $8,699 | $19,692 | $17,874 | $32,230 | | Research and development | $43,469 | $40,393 | $84,091 | $73,840 | | General and administrative | $17,989 | $14,296 | $36,346 | $27,845 | | Loss from operations | $(52,759) | $(34,997) | $(102,563) | $(69,455) | | Net loss | $(50,469) | $(32,923) | $(97,347) | $(64,481) | | Net loss per share | $(0.31) | $(0.25) | $(0.60) | $(0.50) | [Unaudited Consolidated Statements of Cash Flows](index=9&type=section&id=Unaudited%20Consolidated%20Statements%20of%20Cash%20Flows) This section outlines the cash inflows and outflows from operating, investing, and financing activities for the six months ended June 30, 2025, and 2024 Consolidated Statements of Cash Flows Highlights (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(109,051) | $(60,900) | | Net cash used in investing activities | $(471) | $(469) | | Net cash provided by financing activities | $15,848 | $15,163 | | Net decrease in cash, cash equivalents, and restricted cash | $(93,573) | $(46,361) | [Notes to Unaudited Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Unaudited%20Consolidated%20Financial%20Statements) This section provides additional details and explanations for the financial statements, including business overview, liquidity, and revenue recognition - The company is a clinical-stage biotechnology firm focused on RNA medicines, with a diversified pipeline including programs in obesity, AATD, DMD, and HD[28](index=28&type=chunk) - As of June 30, 2025, the company had **$208.5 million in cash and cash equivalents** and expects this to be sufficient to fund operations for at least the next twelve months. An additional **$24.9 million** was raised post-quarter end via its at-the-market program[32](index=32&type=chunk) - Revenue from the GSK Collaboration Agreement was **$8.7 million for Q2 2025** and **$17.9 million for the first six months of 2025**. As of June 30, 2025, unsatisfied performance obligations under the agreement totaled approximately **$66.2 million**[53](index=53&type=chunk)[57](index=57&type=chunk) - The Takeda collaboration expired in October 2024, resulting in **no revenue from this agreement in 2025**, compared to **$0.8 million** in the first six months of 2024[60](index=60&type=chunk)[61](index=61&type=chunk) Research and Development Expenses by Program (in thousands) | Program | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | | :--- | :--- | :--- | | AATD program | $1,846 | $3,292 | | INHBE program (Obesity) | $3,515 | $6,054 | | DMD program | $2,681 | $5,719 | | HD program | $789 | $1,956 | | Other R&D expenses | $34,638 | $67,070 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=21&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's business, clinical pipeline progress, financial results, and liquidity, noting decreased revenue, increased expenses, and sufficient cash for the next twelve months [Overview and Current Programs](index=21&type=section&id=Overview%20and%20Current%20Programs) This section provides an overview of the company's clinical-stage biotech platform and updates on key development programs in obesity, AATD, DMD, and HD - The company is a clinical-stage biotech utilizing its PRISM® platform to develop RNA medicines across four modalities: RNA editing (AIMers), RNA interference (siRNA), splicing, and antisense silencing[72](index=72&type=chunk)[75](index=75&type=chunk) - **Obesity (WVE-007):** Initiated INLIGHT, a Phase 1 trial in obesity, in February 2025. Dosing is complete in the expanded 240 mg cohort, with data expected in Q4 2025[83](index=83&type=chunk)[85](index=85&type=chunk) - **AATD (WVE-006):** First-ever clinical demonstration of RNA editing in humans. Data from the 200 mg single and multidose cohorts of the RestorAATion-2 trial are expected in Q3 2025. The program is exclusively licensed to GSK[88](index=88&type=chunk)[89](index=89&type=chunk)[90](index=90&type=chunk) - **DMD (WVE-N531):** Positive 48-week data from the FORWARD-53 trial showed statistically significant functional improvement. The company plans to file a New Drug Application (NDA) in 2026 for accelerated approval with monthly dosing[97](index=97&type=chunk)[99](index=99&type=chunk) - **HD (WVE-003):** Positive Phase 1b/2a data showed significant reduction in mHTT. The company is preparing for a global Phase 2/3 study and expects to submit an IND in H2 2025[105](index=105&type=chunk)[107](index=107&type=chunk) [Results of Operations](index=30&type=section&id=Results%20of%20Operations) This section analyzes the company's financial performance for the three and six months ended June 30, 2025, compared to 2024, focusing on revenue, expenses, and net loss Comparison of Results for the Three Months Ended June 30 (in thousands) | Metric | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Revenue | $8,699 | $19,692 | $(10,993) | | Research and development | $43,469 | $40,393 | $3,076 | | General and administrative | $17,989 | $14,296 | $3,693 | | Net loss | $(50,469) | $(32,923) | $(17,546) | - The decrease in Q2 2025 revenue was primarily driven by lower revenue recognized under the GSK Collaboration Agreement[126](index=126&type=chunk) - The increase in Q2 2025 R&D expenses was mainly due to a **$6.8 million increase in unallocated R&D costs** and a **$1.9 million increase for the INHBE (obesity) program**, partially offset by decreases in spending on the HD, DMD, and AATD programs[128](index=128&type=chunk)[131](index=131&type=chunk) Comparison of Results for the Six Months Ended June 30 (in thousands) | Metric | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Revenue | $17,874 | $32,230 | $(14,356) | | Research and development | $84,091 | $73,840 | $10,251 | | General and administrative | $36,346 | $27,845 | $8,501 | | Net loss | $(97,347) | $(64,481) | $(32,866) | [Liquidity and Capital Resources](index=33&type=section&id=Liquidity%20and%20Capital%20Resources) This section discusses the company's cash position, funding sources, and cash flow activities, confirming sufficient liquidity for the next twelve months - As of June 30, 2025, the company had cash and cash equivalents of **$208.5 million**. Subsequent to the quarter-end, it received an additional **$24.9 million** in net proceeds from its "at-the-market" equity program[140](index=140&type=chunk) - Management expects that existing cash and cash equivalents are sufficient to fund operations for at least the next twelve months[141](index=141&type=chunk) - Net cash used in operating activities increased to **$109.1 million** for the six months ended June 30, 2025, from **$60.9 million** in the same period of 2024, primarily due to a higher net loss and changes in operating assets and liabilities[145](index=145&type=chunk)[146](index=146&type=chunk) - Net cash provided by financing activities was **$15.8 million** for the first six months of 2025, mainly from **$12.4 million** in proceeds from the "at-the-market" equity program and **$3.0 million** from share option exercises[149](index=149&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=37&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company identifies primary market risks including interest rates, foreign exchange, inflation, and capital market volatility, none of which materially impacted financial results - The company's primary market risk exposures are from interest rates, foreign currency exchange rates, inflation, and capital market volatility[158](index=158&type=chunk) - Changes in foreign currency exchange rates and inflation did not have a material impact on financial results for the reported periods[160](index=160&type=chunk)[161](index=161&type=chunk) [Controls and Procedures](index=37&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded the company's disclosure controls and procedures were effective as of June 30, 2025, with no material changes to internal control over financial reporting - Based on an evaluation as of June 30, 2025, the principal executive officer and principal financial officer concluded that the company's disclosure controls and procedures were effective[163](index=163&type=chunk) - There were no changes in internal control over financial reporting during the quarter that have materially affected, or are reasonably likely to materially affect, such controls[164](index=164&type=chunk) PART II - OTHER INFORMATION [Legal Proceedings](index=38&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any material legal proceedings - The company is not currently a party to any material legal proceedings[165](index=165&type=chunk) [Risk Factors](index=38&type=section&id=Item%201A.%20Risk%20Factors) This section refers readers to the comprehensive risk factors detailed in the company's 2024 Annual Report on Form 10-K - The company directs investors to review the risk factors detailed in its 2024 Annual Report on Form 10-K[166](index=166&type=chunk) [Other Information](index=38&type=section&id=Item%205.%20Other%20Information) This section discloses the adoption of Rule 10b5-1 trading plans by two executive officers, the CEO and CTO, for potential sales of company shares - During Q2 2025, two executive officers adopted Rule 10b5-1 trading plans for the sale of company securities[171](index=171&type=chunk) - On May 19, 2025, CEO Paul B. Bolno adopted a plan for the sale of up to **2,563,388 ordinary shares**, active until November 15, 2025[172](index=172&type=chunk) - On May 16, 2025, CTO Chandra Vargeese adopted a plan for the sale of up to **94,600 ordinary shares**, active until November 20, 2025[173](index=173&type=chunk)

Exhibit 99.1 Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update Cash and cash equivalents of $208.5 million as of June 30, 2025, with runway expected into 2027 Investor conference call and webcast at 8:30 a.m. ET today CAMBRIDGE, Mass., July 30, 2025 – Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the second quar ...